66958-66-5

Upstream product

• 109885-41-8 5-(chloromethyl)-2,3,5-trimethylcyclohexa-2,5-diene-1,4-dione 
• 173392-05-7 C₂₁H₃₇Al 
• 4537-09-1 1,4-dimethoxy-2,3,5-trimethyl-benzene 
• 54757-17-4 1-chloromethyl-2,5-dimethoxy-3,4,6-trimethyl-benzene 
• 75-24-1 trimethylaluminum 
• 22842-11-1 (5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-1-yne 

Relevant academic research and scientific papers

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed,

An expeditious route to CoQ(n), Vitamins K1 and K2, and related allylated para-quinones utilizing Ni(0) catalysis

Coupling reactions between vynylalanes and chloromethylated para-quinones, mediated by catalytic amounts of Ni(0), lead directly to allylated products, including coenzyme Q, and vitamins K1 and K2.